Prospective study of Na[¹⁸F]F PET/CT for cancer staging in morbidly obese patients compared with [^99mTc]Tc-MDP whole-body planar, SPECT and SPECT/CT

References

• WHO. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. WHO Technical Report Series 894. Geneva: World Health Organization; 2000.
   Google Scholar
• World Health Organization. Obesity and Overweight. 2021. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
   Google Scholar
• Prevalence of Obesity. World Obesity Federation. 2021. https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity
   Google Scholar
• Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15(6):556–565.
   PubMed Web of Science ®Google Scholar
• Sinicrope FA, Dannenberg AJ. Obesity and breast cancer prognosis: weight of the evidence. J Clin Oncol. 2011;29(1):4–7.
   PubMed Web of Science ®Google Scholar
• Donohoe KJ, Cohen EJ, Giammarile F, et al. Appropriate use criteria for bone scintigraphy in prostate and breast cancer: Summary and excerpts. J Nucl Med. 2017;58(4):14N–17N.
   PubMed Web of Science ®Google Scholar
• Weiner GM, Jenicke L, Mueller V, et al. Artifacts and non-osseous uptake in bone scintigraphy: imaging reports of 20 cases. Radiol Oncol. 2001;35:185–191.
   Google Scholar
• Usmani S, Marafi F, Ahmed N, et al. Diagnostic challenge of staging metastatic bone disease in the morbidly obese patients: a primary study evaluating the usefulness of 18F-Sodium fluoride (NaF) PET-CT. Clin Nucl Med. 2017;42(11):829–836.
   PubMed Web of Science ®Google Scholar
• WHO expert consultation Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. The Lancet. 2004;363(9403):157–163.
   PubMed Web of Science ®Google Scholar
• Segall G, Delbeke D, Stabin MG, et al. SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. J Nucl Med. 2010;51(11):1813–1820.
   PubMed Web of Science ®Google Scholar
• Beheshti M, Mottaghy FM, Paycha F, et al. 18 F-NaF PET/CT: EANM procedure guidelines for bone imaging. Eur J Nucl Med Mol Imaging. 2015;42(11):1767–1777.
   PubMed Web of Science ®Google Scholar
• Van den Wyngaert T, Strobel K, Kampen WU, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging. 2016;43(9):1723–1738.
   PubMed Web of Science ®Google Scholar
• Palmedo H, Marx C, Ebert A, et al. Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging. 2014;41(1):59–67.
   PubMed Web of Science ®Google Scholar
• Hamaoka T, Costelloe CM, Madewell JE, et al. Tumour response interpretation with new tumour response criteria vs the world health organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer. 2010;102(4):651–657.
   PubMed Web of Science ®Google Scholar
• Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP publication 53.ICRP publication 106. Approved by the commission in October 2007. Ann ICRP. 2008;38(1-2):1–197.
   PubMedGoogle Scholar
• ICRP Radiation dose to patients from radiopharmaceuticals (addendum to ICRP publication 53). ICRP publication 80. Ann ICRP. 1998;28:1–126.
   Google Scholar
• Christner J, Kofler J, McCollough CH. Estimating effective dose for CT using dose-length product compared with using organ doses: consequences of adopting international commission on radiological protection publication 103 or dual-energy scanning. AJR Am J Roentgenol. 2010;194(4):881–889.
   PubMed Web of Science ®Google Scholar
• Tateishi U, Morita S, Taguri M, et al. A eta-analysis of 18F-fluoride positron emission tomography for assessment of metastatic bone tumor. Ann Nucl Med. 2010;24(7):523–531.
   PubMed Web of Science ®Google Scholar
• Roldán-Nofuentes JA. Compbdt: an R program to compare two binary diagnostic tests subject to a paired design. BMC Med Res Methodol. 2020;20(1):143.
   PubMed Web of Science ®Google Scholar
• DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–845.
   PubMed Web of Science ®Google Scholar
• Shim SR, Kim SJ, Lee J. Diagnostic test accuracy: application and practice using R software. Epidemiol Health. 2019;41:e2019007.
   PubMed Web of Science ®Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. Ser B (Methodol). 1995;57(1):289–300.
   Google Scholar
• Azad GK, Taylor B, Rubello D, et al. Molecular and functional imaging of bone metastases in breast and prostate cancers: an overview. Clin Nucl Med. 2016;41(1):e44– 50–e50.
   PubMed Web of Science ®Google Scholar
• Schirrmeister H, Guhlmann A, Elsner K, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med. 1999;40(10):1623–1629.
   PubMed Web of Science ®Google Scholar
• Even-Sapir E, Metser U, Mishani E, et al. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287–297.
   PubMed Web of Science ®Google Scholar
• Chakraborty D, Bhattacharya A, Mete UK, et al. Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma. Clin Nucl Med. 2013;38(8):616–621.
   PubMed Web of Science ®Google Scholar
• Liu Y, Sheng J, Dong Z, et al. The diagnostic performance of 18F-fluoride PET/CT in bone metastases detection: a meta-analysis. Clin Radiol. 2019;74(3):196–206.
   PubMed Web of Science ®Google Scholar
• Sheikhbahaei S, Jones KM, Werner RA, et al. 18F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies. Ann Nucl Med. 2019;33(5):351–361.
   PubMed Web of Science ®Google Scholar
• Guezennec C, Keromnes N, Robin P, et al. Incremental diagnostic utility of systematic double-bed SPECT/CT for bone scintigraphy in initial staging of cancer patients. Cancer Imaging. 2017;17(1):16.
   PubMedGoogle Scholar
• Rager O, Nkoulou R, Exquis N, et al. Whole-Body SPECT/CT versus planar bone scan with targeted SPECT/CT for metastatic workup. Biomed Res Int. 2017;2017:7039406.
   PubMed Web of Science ®Google Scholar
• Keidar Z, Israel O, Krausz Y. SPECT/CT in tumor imaging: technical aspects and clinical applications. Semin Nucl Med. 2003;33(3):205–218.
   PubMed Web of Science ®Google Scholar
• Schirrmeister H, Glatting G, Hetzel J, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42(12):1800–1804.
   PubMed Web of Science ®Google Scholar
• Fonager RF, Zacho HD, Langkilde NC, et al. Diagnostic test accuracy study of (18)F-sodium fluoride PET/CT, (99 m)Tc-labelled diphosphonate SPECT/CT, and planar bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer. Am J Nucl Med Mol Imaging. 2017;7:218–227.
   PubMed Web of Science ®Google Scholar
• Even-Sapir E, Keidar Z, Bar-Shalom R. Hybrid imaging (SPECT/CT and PET/CT)–improving the diagnostic accuracy of functional/metabolic and anatomic imaging. Semin Nucl Med. 2009;39(4):264–275.
   PubMed Web of Science ®Google Scholar
• Strobel K, Burger C, Seifert B, et al. Characterization of focal bone lesions in the axial skeleton: performance of planar bone scintigraphy compared with SPECT and SPECT fused with CT. AJR Am J Roentgenol. 2007;188(5):W467–W474.
   PubMed Web of Science ®Google Scholar
• Basu S, Alavi A. Bone marrow and not bone is the primary site for skeletal metastasis: critical role of [18F] fluorodeoxyglucose positron emission tomography in this setting. J Clin Oncol. 2007;25(10):1297–1299.
   PubMed Web of Science ®Google Scholar
• Gauthé M, Aveline C, Lecouvet F, et al. Impact of sodium 18F-fluoride PET/CT, 18F-fluorocholine PET/CT and whole-body diffusion-weighted MRI on the management of patients with prostate cancer suspicious for metastasis: a prospective multicentre study. World J Urol. 2019;37(8):1587–1595.
   PubMed Web of Science ®Google Scholar
• Hillner BE, Siegel BA, Hanna L, et al. Impact of 18F-fluoride PET in patients with known prostate cancer: initial results from the national oncologic PET registry. J Nucl Med. 2014;55(4):574–581.
   PubMed Web of Science ®Google Scholar
• Hillner BE, Siegel BA, Hanna L, et al. Impact of (18)F-fluoride PET on intended management of patients with cancers other than prostate cancer: results from the national oncologic PET registry. J Nucl Med. 2014;55(7):1054–1061.
   PubMed Web of Science ®Google Scholar
• Tateishi U, Morita S, Inoue T. Diagnostic accuracy of 18F-fluoride PET and PET/CT in patients with bone metastases: a systematic review and meta-analysis update. Clin Transl Imaging. 2013;1(2):123–134.
   Google Scholar
• Hetzel M, Arslandemir C, König HH, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res. 2003;18(12):2206–2214.
   PubMed Web of Science ®Google Scholar
• Liang B, Gao Y, Chen Z, et al. Evaluation of effective dose from CT scans for overweight and obese adult patients using the virtual dose software. Radiat Prot Dosimetry. 2017;174(2):216–225.
   PubMed Web of Science ®Google Scholar